Protein Kinase Inhibitors: all 15,038 studies that test it

Page 84 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.

• Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.CompletedNCT05027386Phase 1/2
• A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）CompletedNCT05025631Phase 2
• A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALLStatus unknownNCT05024357Not applicable
• Public Health Emergency: SOLIDARITY TRIAL PhilippinesCompletedNCT05024006Not applicable
• Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma ThrombosisStatus unknownNCT05022628Phase 4
• Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyWithdrawnNCT05022394Phase 1/2
• Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS LymphomaStatus unknownNCT05021770Phase 1/2
• Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLCCompletedNCT05021328Phase 1
• Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHDStatus unknownNCT05021276Phase 4
• Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2
• A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk MyelofibrosisCompletedNCT05020652Phase 2
• A Clinical Trial of the Orelabrutinib in the Management of Refractory ITPStatus unknownNCT05020288Phase 2
• Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Phase 2
• Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung CancerCompletedNCT05017025Phase 1/2
• Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerStatus unknownNCT05016869Phase 1/2
• Efficacy and Safety of Baricitinib in Sjogren's SyndromeCompletedNCT05016297Phase 2
• Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
• Alectinib in Neo-adjuvant Treatment of Stage III NSCLCActive, not recruitingNCT05015010Phase 2
• A Study of JNJ-64251330 in Participants With Familial Adenomatous PolyposisCompletedNCT05014360Phase 1
• Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
• TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Phase 2
• Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland CarcinomasStatus unknownNCT05013515Not applicable
• Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male SubjectsCompletedNCT05012670Phase 1
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I NeurofibromatosisTerminatedNCT05011019Phase 1/2
• BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid TumorsWithdrawnNCT05010096Phase 1
• Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3
• Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]AdavosertibTerminatedNCT05008913Phase 1
• Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingNCT05007938Phase 2
• ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05007873Phase 2
• Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
• Study on the Treatment of Differentiated Thyroid Carcinoma with AnlotinibActive, not recruitingNCT05007093Phase 2
• Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)CompletedNCT05006768Phase 1
• Single and Multiple Ascending Dose Study of KN-002CompletedNCT05006521Phase 1
• A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.Status unknownNCT05005468Phase 2
• Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRCStatus unknownNCT05004831Phase 2
• Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+GoserelinStatus unknownNCT05004142Phase 2
• Acalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT05004064Phase 2
• A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male ParticipantsCompletedNCT05003089Phase 1
• Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung CancerActive, not recruitingNCT05003037Phase 2
• Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Active, not recruitingNCT05002777Phase 2
• Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsCompletedNCT05002231Phase 1
• Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer PatientsCompletedNCT05002140Phase 1
• Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyCompletedNCT05001971Phase 2
• Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLCStatus unknownNCT05001412Phase 1
• A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.Status unknownNCT04999878Phase 4
• Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2
• A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )Status unknownNCT04998760Phase 2
• Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedNCT04997902Phase 1/2
• Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
• Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung CancerStatus unknownNCT04996771Phase 1/2
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• Effect of Rapamycin to Improve Cardiac Function in Frail Older AdultsCompletedNCT04996719Phase 1
• Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic LeukemiaCompletedNCT04996160Phase 1
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
• A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsWithdrawnNCT04994002Phase 1
• Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping MutationsWithdrawnNCT04992858Phase 2
• TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCCStatus unknownNCT04992143Phase 2
• Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune ScoreStatus unknownNCT04989855Phase 2
• Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3
• A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3CompletedNCT04985955Phase 1
• To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.Active, not recruitingNCT04985851Not applicable
• The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line TreatmentActive, not recruitingNCT04984369Phase 2
• Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male ParticipantsCompletedNCT04982991Phase 1
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor CancerTerminatedNCT04982926Phase 1
• Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass OpacitiesStatus unknownNCT04982900Phase 2
• A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)Active, not recruitingNCT04980872Phase 2
• Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active, not recruitingNCT04980833Phase 2
• Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of MelanomaStatus unknownNCT04979585Phase 2
• A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter SyndromeTerminatedNCT04978779Phase 1
• the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung CancerStatus unknownNCT04978753Phase 2
• Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
• Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) PatientsCompletedNCT04977661Phase 4
• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Active, not recruitingNCT04976634Phase 2
• A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04976270Phase 1
• Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid TumorsCompletedNCT04975958Phase 1
• ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast CancerStatus unknownNCT04975451Phase 2
• First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical CancerTerminatedNCT04974944Phase 2
• Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerStatus unknownNCT04974879Phase 2
• Effect of Tofacitinib in Treating ANCA-associated VasculitisCompletedNCT04973033Not applicable
• A Phase 1b Study of ZN-c3 in Chinese SubjectsStatus unknownNCT04972422Phase 1
• Phase I BLASST-3 TrialWithdrawnNCT04972253Phase 1
• Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsCompletedNCT04971746Phase 1
• Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003Status unknownNCT04970914Phase 2
• Baricitinib in Hospitalized Covid-19 Patients With Diabetes MellitusWithdrawnNCT04970719Phase 3
• A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionStatus unknownNCT04970693Phase 2
• To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic PopulationsCompletedNCT04969965Phase 1
• A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLCStatus unknownNCT04967625Phase 2
• SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaActive, not recruitingNCT04967521Phase 3
• Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC PatientsCompletedNCT04967079Phase 1
• Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerTerminatedNCT04965818Phase 1
• A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
• A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04965090Phase 2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Phase 3
• Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerStatus unknownNCT04963595Phase 2
• Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)CompletedNCT04963088Phase 1/2
• Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryCompletedNCT04962958Phase 2

← Protein Kinase Inhibitors overview